Psychosis is a common and distressing symptom in people with Alzheimer disease, and few
safe and effective treatments are available. However, new approaches to symptom …

Objective To investigate whether cholinesterase inhibitors (ChEIs) are associated with
slower cognitive decline in Alzheimer dementia and decreased risk of severe dementia or …

Introduction Cholinergic dysfunction, demonstrated in the late 1970s and early 1980s, led to
the introduction of acetylcholinesterase inhibitors (AChEIs) in 1993 (Tacrine) to enhance …

We evaluated the effect of Acetyl-cholinesterase-inhibitors (AChEIs) on cognitive decline
and overall survival in a large sample of older patients with late onset Alzheimer's disease …

This study presents hydrogel nanoparticles made of chitosan and tripolyphosphate via
ionotropic gelation technique to evaluate their potential for the association of deferoxamine …

Neuropsychiatric or behavioral symptoms of dementia encompass a series of disorders,
such as anxiety, depression, apathy, psychosis, and agitation, all commonly present in …

The basal forebrain cholinergic nuclei (BFCN) provide the main cholinergic input to
prefrontal cortices, the hippocampi, and amygdala. These structures are highly relevant for …

Introduction Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide
symptomatic benefit for some individuals with dementia; however, there are circumstances …

Background Optimal use of psychotropic medications for people living with dementia is
important. By finding potentially modifiable factors, dementia care teams may find solutions …

Alzheimer's disease is the most common cause of dementia globally. Its prevalence will
increase considerably in the years to come, in pace with the increasing proportion of older …